1192752-15-0

Basic information

• Product Name: [2-(4-aminophenyl)ethyl]-(5,6-diphenylfuro[2,3-d]pyrimidin-4-yl)-amine
• Synonyms: [2-(4-aminophenyl)ethyl]-(5,6-diphenylfuro[2,3-d]pyrimidin-4-yl)-amine
• CAS NO: 1192752-15-0
• Molecular Weight: 406.487
• Mol File: 1192752-15-0.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: [2-(4-aminophenyl)ethyl]-(5,6-diphenylfuro[2,3-d]pyrimidin-4-yl)-amine(CAS DataBase Reference)
• NIST Chemistry Reference: [2-(4-aminophenyl)ethyl]-(5,6-diphenylfuro[2,3-d]pyrimidin-4-yl)-amine(1192752-15-0)
• EPA Substance Registry System: [2-(4-aminophenyl)ethyl]-(5,6-diphenylfuro[2,3-d]pyrimidin-4-yl)-amine(1192752-15-0)

Safety Data

• Hazardous Substances Data: 1192752-15-0(Hazardous Substances Data)

Upstream product

• 65148-07-4 4-chloro-5,6-diphenylfuro[2,3-d]pyrimidine 
• 13472-00-9 p-Aminophenethylamine 

Downstream Products

• 1192754-37-2 1-(4-{2-[(5,6-diphenylfuro[2,3-d]pyrimidin-4-yl)amino]ethyl}phenyl)-3-(5-methyl-1H-pyrazol-3-yl)urea 
• 1235310-93-6 N-{4-[2-(5,6-diphenylfuro[2,3-d]pyrimidin-4-ylamino)ethyl]-phenyl}benzenesulfonamide 
• 1192752-20-7 N-{4-[2-(5,6-diphenylfuro[2,3-d]pyrimidin-4-ylamino)ethyl]-phenyl}benzamide 
• 1192752-22-9 1-{4-[2-(5,6-diphenylfuro[2,3-d]pyrimidin-4-ylamino)ethyl]-phenyl}-3-phenylurea 
• 1192753-40-4 1-cyclohexyl-3-(4-{2-[(5,6-diphenylfuro[2,3-d]pyrimidin-4-yl)amino]ethyl}phenyl)urea 
• 1192752-26-3 1-(4-{2-[(5,6-diphenylfuro[2,3-d]pyrimidin-4-yl)amino]-ethyl}phenyl)-3-methylurea 
• 1192753-41-5 1-(4-{2-[(5,6-diphenylfuro[2,3-d]pyrimidin-4-yl)amino]-ethyl}phenyl)-3-(4-methoxyphenyl)urea 
• 1192753-30-2 1-(4-{2-[(5,6-diphenylfuro[2,3-d]pyrimidin-4-yl)amino]-ethyl}phenyl)-3-(4-fluorophenyl)urea 
• 1192752-24-1 1-(4-{2-[(5,6-diphenylfuro[2,3-d]pyrimidin-4-yl)amino]-ethyl}phenyl)urea 
• 1192752-30-9 1-benzyl-3-(4-{2-[(5,6-diphenylfuro[2,3-d]pyrimidin-4-yl)-amino]ethyl}phenyl)urea 

Relevant articles and documents

Optimization of ligand and lipophilic efficiency to identify an in vivo active furano-pyrimidine aurora kinase inhibitor

Ligand efficiency (LE) and lipophilic efficiency (LipE) are two important indicators of "drug-likeness", which are dependent on the molecule's activity and physicochemical properties. We recently reported a furano-pyrimidine Aurora kinase inhibitor 4 (LE = 0.25; LipE = 1.75), with potent activity in vitro; however, 4 was inactive in vivo. On the basis of insights obtained from the X-ray co-crystal structure of the lead 4, various solubilizing functional groups were introduced to optimize both the activity and physicochemical properties. Emphasis was placed on identifying potential leads with improved activity as well as better LE and LipE by exercising tight control over the molecular weight and lipophilicity of the molecules. Rational optimization has led to the identification of Aurora kinase inhibitor 27 (IBPR001; LE = 0.26; LipE = 4.78), with improved in vitro potency and physicochemical properties, resulting in an in vivo active (HCT-116 colon cancer xenograft mouse model) anticancer agent.

FUSED BICYCLIC PYRIMIDINE COMPOUNDS AS AURORA KINASE INHIBITORS

Fused bicyclic pyrimidine compounds of formula (I): wherein R1, R3, R4, X1, X2, Y, Z, A, B, C, D, n, and the two bonds are defined herein. Also disclosed are a method for inhibiting Aurora kinase activity and a method for treating cancer with these compounds.